Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

As of late 2024, only 14 state Medicaid programs cover GLP-1 drugs like Wegovy, Saxenda, or Zepbound for the treatment of obesity. These states are: California, Connecticut, Indiana, Maryland, ...

The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...

Expanding coverage of the drugs would have ... In an effort to reduce costs, Medicare has selected Novo Nordisk’s Wegovy for negotiations to lower prices under a law passed by a Democratic ...

The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

Cigna's Evernorth is rolling out a new pharmacy benefit management program that caps members' monthly cost for key GLP-1 ...

Despite the price drops, the drugs remain costly. Novo Nordisk cut the price of Wegovy by 23 percent for cash payments from ...

Eliminating coverage for these drugs ... Between 2022 and 2023, Wegovy prescriptions in the Medi-Cal program jumped from 15,000 to 181,000, data from the U.S. Centers for Medicaid and Medicare ...

Wegovy belongs to a pricey class of drugs called GLP-1s (short for glucagon-like peptide-1 agonists) that have upended the ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.